Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting

SUZHOU,China,June 6,2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628),a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery,research,development and manufacturing of antibody-based therapeutics,has presented updated data of Cohort C from a phase I/IIa,multi-center study of Osemitamab (TST001) in combination with Capecitabine and Oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The data showed that Osemitamab (TST001) has durable anti-tumor activity in all the study population including both high and low to median CLDN18.2-expressing gastric cancer. These data will support the upcoming global Phase III pivotal trial to be initiated in the second half of 2023.

Adding an anti-claudin18.2 (CLDN18.2) antibody to a chemotherapy is a clinically validated approach for patients with high CLDN18.2 expressing gastric tumors. Osemitamab (TST001) is a potential best-in-class humanized antibody with higher CLDN18.2 binding affinity and lower fucose,resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. Pre-clinical studies showed that Osemitamab (TST001) has stronger tumor growth inhibition effect than the Zolbetuximab (IMAB362)-analog at the same dose,regardless of CLDN18.2 expression levels.

Title

Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin (CAPOX) as a First-Line Treatment of Advanced G/GEJ Cancer-updated Data of Cohort C from a Phase I/IIa,Multi-center Study (TranStar102/TST001-1002)

Study Design

Transtar-102 (NCT04495296) is an ongoing Phase I/II,open-label,multi-cohort,multi-center clinical study in China to evaluate the efficacy and safety of Osemitamab (TST001) plus CAPOX as a first-line treatment for Chinese patients with unresectable locally advanced or metastatic G/GEJ cancer who had not received prior systemic treatment for advanced disease. Positive CLDN18.2 expression (membranous staining ≥1+ intensity in≥10% of tumor cells) as assessed centrally using the LDT assay was required in the expansion phase only.

Safety Results

As of April 21,2023,15 patients received Osemitamab (TST001) in the escalation phase and 49 patients at dose of 6mg/kg Q3W in the expansion group. Treatment-emergent adverse events (TEAEs) were mostly grade 1-2 and the most common TEAEs include nausea,hypoalbuminemia,anemia and vomiting. Only one patient experienced grade 3 nausea and vomiting at the dose of 6mg/kg,one patient experienced grade 3 hypoalbuminemia at the dose of 8mg/kg. There were no grade 4 adverse events.

Efficacy Results

As of April 21,among the 49 patients of 6mg/kg Q3W dose expansion group,42 patients had measurable lesions and at least one post treatment tumor assessment,28 (66.7%) achieved partial response. Estimated median duration of response was 9.9 months in 34 responders from all dose groups. Estimated median progression-free survival was 9.5 months from all dose groups.

Conclusions

The safety profile of Osemitamab (TST001) is mainly characterized by manageable on-target,off-tumor side effects; most of these AEs are of grade 1 or 2.

The addition of Osemitamab (TST001) to CAPOX for first-line treatment of CLDN18.2 expressing (≥10% tumor cells with membrane staining≥1+) patients with G/GEJ cancer leads to improved efficacy outcomes as compared to historical controls,with no trend to lower efficacy with lower levels of expression.

"We are very encouraged by these longer follow up data. Based on other clinical trials results,we know that long term efficacy endpoints such as PFS and DOR,rather than ORR,are critical indicators of the potential of Osemitamab. We selected patients with CLDN81.2 expressing tumors,corresponding to around 55% of all cases of G/GEJ cancer,and the benefit risk of Osemitamab in combination with CAPOX in that large group of patients is extremely favorable. We look forward to initiating the Phase III trial for Osemitamab (TST001)." said Dr. Caroline Germa,Transcenta's Executive Vice President,Global Medicine Development and Chief Medical Officer.

The full text of posters is available on Transcenta's website: https://www.transcenta.com/Scientific_Publications.html

About Osemitamab (TST001)

Osemitamab (TST001) is a high affinity humanized anti- CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("ADCC") and complement-dependent cytotoxicity ("CDC") activities and potent anti-tumor activities in tumor xenograft models. Osemitamab (TST001) is the second most advanced CLDN18.2 targeting antibody being developed globally. Osemitamab (TST001) is generated using Transcenta's Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab (TST001) kills CLDN18.2 expressing tumor cells by mechanisms of ADCC and CDC. Leveraging advanced bioprocessing technology,the fucose content of Osemitamab (TST001) was significantly reduced during the production,which further enhanced NK cells mediated ADCC activity of Osemitamab (TST001). Clinical trials for Osemitamab (TST001) are ongoing in the U.S. and China (NCT05190575,NCT04396821,NCT04495296,NCT05608785 / CTR20201281). Osemitamab (TST001) was granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer.

About Transcenta Holding Limited

Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery,development and manufacturing.

Transcenta has established global footprint,with Headquarters and Discovery,Clinical and Translational Research Center in Suzhou,Process and Product Development Center and Manufacturing Facility in Hangzhou,and Clinical Development Centers in Princeton,US and in Beijing,Shanghai and Guangzhou of China,and Business Development Center in Boston and Los Angeles,US. Transcenta has also initiated the construction of the Group Headquarters and the second high-end biopharmaceutical facility with HiCB as its core technology in Suzhou Industrial Park. Transcenta is developing 13 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

For more information,please visit www.transcenta.com and https://www.linkedin.com/company/transcenta.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are,by their nature,subject to significant risks and uncertainties. The words "anticipate","believe","estimate","expect","intend" and similar expressions,as they relate to Transcenta,are intended to identify certain of such forward-looking statements. Transcenta does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs,assumptions,expectations,estimates,projections and understandings of the management of Transcenta with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks,uncertainties and other factors,some of which are beyond Transcenta's control and are difficult to predict. Consequently,actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business,Transcenta's competitive environment and political,economic,legal and social conditions.

Transcenta,the Directors and the employees of Transcenta assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.